These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

461 related items for PubMed ID: 27566699

  • 1. Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal.
    Ramaekers BLT, Riemsma R, Tomini F, van Asselt T, Deshpande S, Duffy S, Armstrong N, Severens JL, Kleijnen J, Joore MA.
    Pharmacoeconomics; 2017 Feb; 35(2):191-202. PubMed ID: 27566699
    [Abstract] [Full Text] [Related]

  • 2. Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Büyükkaramikli NC, Blommestein HM, Riemsma R, Armstrong N, Clay FJ, Ross J, Worthy G, Severens J, Kleijnen J, Al MJ.
    Pharmacoeconomics; 2017 Dec; 35(12):1211-1221. PubMed ID: 28656543
    [Abstract] [Full Text] [Related]

  • 3. Sipuleucel-T for the Treatment of Metastatic Hormone-Relapsed Prostate Cancer: A NICE Single Technology Appraisal; An Evidence Review Group Perspective.
    Simpson EL, Davis S, Thokala P, Breeze PR, Bryden P, Wong R.
    Pharmacoeconomics; 2015 Nov; 33(11):1187-94. PubMed ID: 26017401
    [Abstract] [Full Text] [Related]

  • 4. Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Kearns B, Pandor A, Stevenson M, Hamilton J, Chambers D, Clowes M, Graham J, Kumar MS.
    Pharmacoeconomics; 2017 Apr; 35(4):415-424. PubMed ID: 27770303
    [Abstract] [Full Text] [Related]

  • 5. Trifluridine-Tipiracil for Previously Treated Metastatic Colorectal Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Ramaekers BLT, Wolff R, van Giessen A, Pouwels X, Fayter D, Lang S, Armstrong N, Worthy G, Duffy S, Kleijnen J, Joore MA.
    Pharmacoeconomics; 2018 Mar; 36(3):285-288. PubMed ID: 29177842
    [Abstract] [Full Text] [Related]

  • 6. Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Mistry H, Nduka C, Connock M, Colquitt J, Mantopoulos T, Loveman E, Walewska R, Mason J.
    Pharmacoeconomics; 2018 Apr; 36(4):399-406. PubMed ID: 29222670
    [Abstract] [Full Text] [Related]

  • 7. Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Fleeman N, Abdulla A, Bagust A, Beale S, Richardson M, Stainthorpe A, Boland A, Kotas E, McEntee J, Palmer D.
    Pharmacoeconomics; 2018 Mar; 36(3):289-299. PubMed ID: 29178025
    [Abstract] [Full Text] [Related]

  • 8. Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Ramaekers BLT, Wolff RF, Pouwels X, Oosterhoff M, Van Giessen A, Worthy G, Noake C, Armstrong N, Kleijnen J, Joore MA.
    Pharmacoeconomics; 2018 Aug; 36(8):917-927. PubMed ID: 29480455
    [Abstract] [Full Text] [Related]

  • 9. Ponatinib for Treating Acute Lymphoblastic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Stevenson M, Pandor A, Hamilton J, Stevens J, Rowntree C, Martyn-St James M, Rawdin A, Wong R.
    Pharmacoeconomics; 2018 Jul; 36(7):759-768. PubMed ID: 29502175
    [Abstract] [Full Text] [Related]

  • 10. Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Stainthorpe A, Greenhalgh J, Bagust A, Richardson M, Boland A, Beale S, Duarte R, Kotas E, Banks L, Palmer D.
    Pharmacoeconomics; 2018 Oct; 36(10):1153-1163. PubMed ID: 29600384
    [Abstract] [Full Text] [Related]

  • 11. Ticagrelor for Secondary Prevention of Atherothrombotic Events After Myocardial Infarction: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Pouwels XGLV, Wolff R, Ramaekers BLT, Van Giessen A, Lang S, Ryder S, Worthy G, Duffy S, Armstrong N, Kleijnen J, Joore MA.
    Pharmacoeconomics; 2018 May; 36(5):533-543. PubMed ID: 29344794
    [Abstract] [Full Text] [Related]

  • 12. Ibrutinib for Treating Relapsed or Refractory Mantle Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Tappenden P, Simpson E, Hamilton J, Pollard D, Clowes M, Kaltenthaler E, Meiklejohn D, Morley N.
    Pharmacoeconomics; 2019 Mar; 37(3):333-343. PubMed ID: 30246228
    [Abstract] [Full Text] [Related]

  • 13. Fluocinolone Acetonide Intravitreal Implant for Treating Recurrent Non-infectious Uveitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Pouwels XGLV, Petersohn S, Carrera VH, Denniston AK, Chalker A, Raatz H, Armstrong N, Shah D, Witlox W, Worthy G, Noake C, Riemsma R, Kleijnen J, Joore MA.
    Pharmacoeconomics; 2020 May; 38(5):431-441. PubMed ID: 31701471
    [Abstract] [Full Text] [Related]

  • 14. Oral Azacitidine for Maintenance Treatment of Acute Myeloid Leukaemia After Induction Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Witlox W, Grimm S, Howick J, Armstrong N, Ahmadu C, McDermott K, Otten T, Noake C, Wolff R, Joore M.
    Pharmacoeconomics; 2023 Aug; 41(8):857-867. PubMed ID: 37129774
    [Abstract] [Full Text] [Related]

  • 15. Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma : An Evidence Review Group Evaluation of the NICE Single Technology Appraisal.
    Thielen FW, Büyükkaramikli NC, Riemsma R, Fayter D, Armstrong N, Wei CY, Huertas Carrera V, Misso K, Worthy G, Kleijnen J, Corro Ramos I.
    Pharmacoeconomics; 2019 Aug; 37(8):975-984. PubMed ID: 30547368
    [Abstract] [Full Text] [Related]

  • 16. Belimumab for Treating Active Autoantibody-Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Otten T, Riemsma R, Wijnen B, Armstrong N, Stirk L, Gordon C, Ramaekers B, Kleijnen J, Joore M, Grimm S.
    Pharmacoeconomics; 2022 Sep; 40(9):851-861. PubMed ID: 35802295
    [Abstract] [Full Text] [Related]

  • 17. Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Morgan P, Woolacott N, Biswas M, Mebrahtu T, Harden M, Hodgson R.
    Pharmacoeconomics; 2017 Sep; 35(9):909-919. PubMed ID: 28342113
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Lenalidomide with Rituximab for Previously Treated Follicular Lymphoma and Marginal Zone Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Witlox WJA, Grimm SE, Riemsma R, Armstrong N, Ryder S, Duffy S, Carrera VH, Posadzki P, Worthy G, Pouwels XGLV, Ramaekers BLT, Kleijnen J, Joore MA, van Asselt ADI.
    Pharmacoeconomics; 2021 Feb; 39(2):171-180. PubMed ID: 33145711
    [Abstract] [Full Text] [Related]

  • 20. Dinutuximab Beta for Treating Neuroblastoma: An Evidence Review Group and Decision Support Unit Perspective of a NICE Single Technology Appraisal.
    Pennington B, Ren S, Barton S, Bacelar M, Edwards SJ.
    Pharmacoeconomics; 2019 Aug; 37(8):985-993. PubMed ID: 30465228
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.